Premium
Spectrofluorometric determination of alogliptin an antidiabetic drug in pure and tablet form using fluorescamine, a fluorogenic agent: application to content uniformity test
Author(s) -
Derayea Sayed M.,
Gahlan Ahmed A.,
Omar Mahmoud A.,
Saleh Gamal A.,
Haredy Ahmed M.
Publication year - 2020
Publication title -
luminescence
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.428
H-Index - 45
eISSN - 1522-7243
pISSN - 1522-7235
DOI - 10.1002/bio.3812
Subject(s) - fluorescamine , alogliptin , chromatography , chemistry , fluorescence , dipeptidyl peptidase 4 , medicine , physics , quantum mechanics , type 2 diabetes , diabetes mellitus , endocrinology
Alogliptin is an antidiabetic drug that belongs to a group called dipeptidyl peptidase‐4 enzyme inhibitors. As the drug contains a primary amino group in its structure, it readily reacts with fluorescamine in slightly alkaline medium (borate buffer, pH 8.8) to form a highly fluorescent product. Emission of this product was measured at 477 nm (λ ex = 387 nm). The linear range between the fluorescence intensity and the drug concentration was 0.1–0.5 μg ml −1 with a good correlation coefficient (0.9986). Limits of detection and quantitation were 22 and 72 ng ml −1 , respectively. Guidelines of the International Conference for Harmonisation were followed to validate the developed method with acceptable results. Alogliptin content was determined successfully in its commercial dosage form using the fluorescamine method with good recovery (98.60–101.26%). The method has excellent levels of accuracy and precision compared with the reported method as assessed using Student’s t ‐test and Fisher’s exact test. The method was applied successfully for the content uniformity test with high recovery and low relative standard deviation.